We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+10.16%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.87B
AUM Growth
+$199M
Cap. Flow
+$56.8M
Cap. Flow %
1.98%
Top 10 Hldgs %
71.68%
Holding
83
New
11
Increased
14
Reduced
8
Closed
12
Avg Time Held Equity + Options
3.5 quarters
Top 10 Avg Time Held Equity + Options
3.9 quarters
Top 20 Avg Time Held Equity + Options
4.9 quarters
Avg Time Held Equity only
3.6 quarters
Top 10 Avg Time Held Equity only
3.9 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$92.5M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$61.6M
3
RCUS icon
Arcus Biosciences
RCUS
+$55.6M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$34.5M
5
ALEC icon
Alector
ALEC
+$21.1M

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$104M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$35.3M
3
TBIO icon
Translate Bio, Inc. Common Stock
TBIO
+$28.9M
4
NRIX icon
Nurix Therapeutics
NRIX
+$26M
5
KYMR icon
Kymera Therapeutics
KYMR
+$25.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Miscellaneous 1.52%
3 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$429M
$804M 27.96%
11,284,280
– –
2018 Q4
11 quarters
MORF icon
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$224M 7.79%
3,951,566
– –
2019 Q2
9 quarters
ANAB icon
3
AnaptysBio
ANAB
$1.36B
$204M 7.1%
7,521,024
– –
2019 Q4
7 quarters
RCUS icon
4
Arcus Biosciences
RCUS
$2.87B
$179M 6.21%
5,122,359
+1,787,112
+54% +$55.6M
2018 Q1
14 quarters
XNCR icon
5
Xencor
XNCR
$1.75B
$160M 5.57%
4,906,106
– –
2018 Q4
11 quarters
NUVB icon
6
Nuvation Bio
NUVB
$1.66B
$136M 4.74%
13,711,517
– –
2021 Q1
2 quarters
ALEC icon
7
Alector
ALEC
$209M
$114M 3.97%
4,994,970
+752,336
+18% +$21.1M
2021 Q1
2 quarters
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$82.1M 2.86%
464,298
– –
2018 Q4
11 quarters
LKFT icon
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$82M 2.85%
+1,558,749
New +$92.5M
2021 Q3
0 quarters
STTK icon
10
Shattuck Labs
STTK
$551M
$75.6M 2.63%
3,709,072
+390,662
+12% +$8.36M
2020 Q4
3 quarters
ORIC icon
11
Oric Pharmaceuticals
ORIC
$1.17B
$72.5M 2.52%
3,468,944
+376,726
+12% +$7.64M
2020 Q2
5 quarters
KURA icon
12
Kura Oncology
KURA
$874M
$69.8M 2.43%
3,724,437
– –
2015 Q4
23 quarters
RNAM
13
DELISTED
Avidity Biosciences
RNAM
$68M 2.36%
2,759,505
+655,555
+31% +$14.2M
2020 Q2
5 quarters
GRTS icon
14
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$60.1M 2.09%
5,560,748
+2,139,461
+63% +$19.5M
2020 Q4
3 quarters
RLAY icon
15
Relay Therapeutics
RLAY
$3.8B
$43.7M 1.52%
1,385,276
-3,102,500
-69% -$104M
2020 Q3
4 quarters
ITOS icon
16
DELISTED
iTeos Therapeutics
ITOS
$35.2M 1.22%
1,303,157
+267,293
+26% +$6.99M
2020 Q3
4 quarters
NRIX icon
17
Nurix Therapeutics
NRIX
$2.42B
$33.8M 1.17%
1,126,640
-841,310
-43% -$26M
2020 Q3
4 quarters
JANX icon
18
Janux Therapeutics
JANX
$1.05B
$30.5M 1.06%
1,411,975
– –
2021 Q2
1 quarter
DSGN icon
19
Design Therapeutics
DSGN
$612M
$27.4M 0.95%
1,863,098
+603,079
+48% +$10M
2021 Q1
2 quarters
BPMC icon
20
CALL
DELISTED
Blueprint Medicines
BPMC
$25.9M 0.9%
+250,000
New +$23.3M
2021 Q3
0 quarters
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.96B
$25.6M 0.89%
+1,443,800
New +$61.6M
2021 Q3
0 quarters
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$25.2M 0.88%
+1,249,812
New +$34.5M
2021 Q3
0 quarters
AKUS
23
DELISTED
Akouos Inc
AKUS
$22.9M 0.8%
1,975,984
– –
2020 Q2
5 quarters
SLDB icon
24
Solid Biosciences
SLDB
$624M
$22M 0.77%
613,513
– –
2020 Q4
3 quarters
EWTX icon
25
Edgewise Therapeutics
EWTX
$3.94B
$21.2M 0.74%
1,279,175
+55,000
+4% +$995K
2021 Q1
2 quarters
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2021 Portfolio in Review

As of Q3 2021, EcoR1 Capital held 83 positions worth $2.87B, up 7.4% from $2.68B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital's Q3 2021 filing shows 11 new, 14 increased, 8 reduced and 12 closed positions. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M. The largest sale was Relay Therapeutics, an estimated $104M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • EcoR1 Capital's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 1,558,749 shares worth $82M.
  • EcoR1 Capital added most to Arcus Biosciences in Q3 2021, an estimated $55.6M increase.
  • EcoR1 Capital's biggest Q3 2021 reduction was Relay Therapeutics, cutting an estimated $104M.
  • EcoR1 Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $28.9M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $2.87B portfolio in Q3 2021.
  • EcoR1 Capital opened 11 new positions and closed 12 in Q3 2021.
  • EcoR1 Capital's portfolio value rose 7.4% quarter-over-quarter to $2.87B.

Based on EcoR1 Capital's 13F filing for Q3 2021, filed 15 Nov 2021.